Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Whyte

Interventional Pain Medicine Shreveport, LA Medical Doctor

NPI 1821060476 CMS profile 557312

457 Ashley Ridge Blvd, Shreveport, LA 71106

Open in the dashboard

General payments

$38,874

161 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Whyte of Shreveport, LA is reported in the CMS Open Payments database as having received $38,874 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,456 31
2024 General $18,954 60
2023 General $2,536 24
2022 General $203 7
2021 General $119 5
2020 General $201 13
2019 General $404 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Whyte
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to William Whyte were reported at $16,456. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year William Whyte Interventional Pain Medicine median Middle half National median
2019 $404 $684 $216–$2,079 $163
2020 $201 $382 $122–$1,109 $114
2021 $119 $552 $167–$1,554 $132
2022 $203 $605 $187–$1,924 $149
2023 $2,536 $671 $195–$1,915 $160
2024 $18,954 $684 $206–$1,837 $164
2025 $16,456 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $36,202 101 payments
  2. SI-BONE, Inc. $1,904 18 payments
  3. Medtronic USA, Inc. $336 22 payments
  4. Abbott Laboratories $211 8 payments
  5. Boston Scientific Corporation $116 5 payments
  6. Horizon Therapeutics plc $66 5 payments
  7. Avanos Medical $20 1 payment
  8. Eagle Pharmaceuticals, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,514 8 payments
  2. Travel and Lodging $5,759 20 payments
  3. Food and Beverage $4,601 133 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $35,530 83 payments
  2. IFUSE IMPLANT SYSTEM $1,192 4 payments
  3. INTELLIS Spinal Cord Neurostimulation $336 22 payments
  4. Proclaim Family of SCS IPGs $109 3 payments
  5. INCEPTIV $100 5 payments
  6. INTELLIS Spinal Cord Neurostimulation $96 4 payments
  7. VANTA ADAPTIVESTIM $94 1 payment
  8. OSTEOCOOL RF ABLATION SYSTEM $90 3 payments
  9. DUEXIS $66 5 payments
  10. KYPHON EXPRESS II KYPHOPAK TRAY $49 2 payments
  11. Other $285 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

380

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$5,426

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

9.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Generic 12 $2,737
Tizanidine Hcl Generic 123 $1,190
Gabapentin Generic 87 $653
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $261
Tramadol Hcl Generic 73 $242
Celecoxib Generic 15 $207
Clindamycin Hcl Generic 23 $88
Ciprofloxacin Hcl Generic 12 $48

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$177,520

Of which drugs: $494

Medicare patients

171

Average age 76

Services billed

2,903

104 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 47%
Ischemic heart disease 38%
Chronic kidney disease 36%
Osteoporosis 30%
Atrial fibrillation 27%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 33 50 $252
Injection, fentanyl citrate, 0.1 mg J3010 Office 80 170 $123
Injection, propofol, 10 mg J2704 Office 80 1,121 $98
Injection, midazolam hydrochloride, per 1 mg J2250 Office 66 90 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record